Bio-Path Holdings to Present at Major Investment Conference
HOUSTON – Bio-Path Holdings, Inc. (NASDAQ: BPTH), an innovative biotechnology company, is thrilled to announce that Peter Nielsen, the Chief Executive Officer, will be featured in a pre-recorded presentation. This event is scheduled for the H.C. Wainwright 26th Annual Global Investment Conference and will be available on Monday, September 9, 2024, at 7:00 a.m. ET.
What to Anticipate from the Presentation
During this presentation, viewers can expect to gain valuable insights into Bio-Path's groundbreaking technologies and their ambitious initiatives in oncology. The audio of the presentation will be accessible online for investors, providing an in-depth look at the company's current projects and future directions.
About Bio-Path Holdings, Inc.
Bio-Path Holdings has been making remarkable progress in the biotechnology sector with its proprietary DNAbilize liposomal delivery system. This cutting-edge method facilitates the creation of targeted nucleic acid drugs aimed at combating cancer. The lead product, prexigebersen (BP1001), specifically targets blood cancers and is currently in a Phase 2 clinical trial. Additionally, a modified version, BP1001-A, is undergoing a Phase 1/1b study focused on solid tumors.
Pipeline Developments
The company is not stopping there; their pipeline also includes research on BP1002, which targets the Bcl-2 protein to treat various blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. Moreover, there is growing anticipation for the IND application for BP1003, a STAT3 antisense oligonucleotide designed to inhibit the STAT3 pathway. This progress showcases Bio-Path's dedication to addressing challenges in cancer treatment.
Looking Ahead: Future Innovations
As Bio-Path Holdings continues to push the boundaries of innovation, its prospects in oncology appear bright. The company's emphasis on developing drugs that can be administered via intravenous infusion represents a significant advancement in patient care. Stakeholders and potential investors will be closely monitoring updates following the presentation.
Investor Relations Information
For further details about the company's advancements and ongoing projects, visit Bio-Path Holdings’ official website. Investors are encouraged to remain engaged as the company shares insights from the upcoming conference and potential breakthroughs in next-generation cancer therapies.
Frequently Asked Questions
Who is presenting for Bio-Path Holdings at the conference?
Peter Nielsen, the Chief Executive Officer of Bio-Path Holdings, will be presenting.
When will the presentation be available?
The presentation will be available on September 9, 2024, at 7:00 a.m. ET.
What is Bio-Path's lead product candidate?
Bio-Path's lead product candidate is prexigebersen (BP1001), which targets blood cancers.
Where can I find more information about Bio-Path Holdings?
More details can be found on Bio-Path's official website.
What developments are expected in Bio-Path’s drug pipeline?
Bio-Path is actively testing several drug candidates, including BP1001 for blood cancers and BP1002 targeting solid tumors.